2. Neurological Disease

Neurological Disease

Neurological Disease

Related Products

PDF 88.0 MB

A range of neurological disorders, including epilepsy and dystonia, may involve dysfunctional intracortical inhibition, and may respond to treatments that modify it. Parkinson’s is a neurodegenerative disease characterized by increased activity of GABA in basal ganglia and the loss of dopamine in nigrostriatum, associated with rigidity, resting tremor, gait with accelerating steps, and fixed inexpressive face. Neurological deficits, along with neuromuscular involvement, are characteristic of mitochondrial disease, and these symptoms can have a dramatic impact on patient quality of life. Neurological features may be manifold, ranging from neural deafness, ataxia, peripheral neuropathy, migraine, seizures, stroke‐like episodes and dementia and depend on the part of the nervous system affected.

Cat. No. Product Name CAS No. Purity Chemical Structure
  • HY-12273G
    DMH-1 (GMP) 1206711-16-1 98%
    DMH-1 (GMP) is GMP grade DMH-1 (HY-12273). DMH-1 (GMP) is a selective BMP inhibitor. DMH-1 (GMP) upregulates the expression of SOX1. DMH-1 (GMP) increases cardiomyocyte progenitor cells and promotes the differentiation of mouse embryonic stem cells into cardiomyocytes. DMH-1 (GMP) induces the differentiation of hiPSC-derived neural progenitor cells into β3-tubulin-positive neurons.
    DMH-1 (GMP)
  • HY-122799
    Cannabigerovarinic acid 64924-07-8 98%
    Cannabigerovarinic acid is a cannabinoid acid, which is found in Thai Cannabis.
    Cannabigerovarinic acid
  • HY-12288R
    Ozanimod (Standard) 1306760-87-1 98%
    Ozanimod (Standard) is the analytical standard of Ozanimod. This product is intended for research and analytical applications. Ozanimod (RPC-1063), a sphingosine 1-phosphate (S1P) receptor modulator that binds with high affinity selectively to S1P receptor subtypes 1 (S1P1) and 5 (S1P5). Ozanimod has modulate effect for hS1P1 and hS1P5 receptor with EC50s of 1.03 nM and 8.6 nM, respectively. Ozanimod can be used for the research of relapsing multiple sclerosis (MS).
    Ozanimod (Standard)
  • HY-122979
    (+)-Butaclamol hydrochloride 55528-07-9 98%
    (+)-Butaclamol hydrochloride is a neuroleptic agent with dopamine receptor-blocking activity. (+)-Butaclamol hydrochloride is (+)- enantiomer of butaclamol.
    (+)-Butaclamol hydrochloride
  • HY-123001
    Nomelidine 60324-59-6 98%
    Nomelidine is the metabolite of Zimelidine (HY-118835), that exhibits antidepressant and analgesic properties.
    Nomelidine
  • HY-123142
    RX809055AX 122566-12-5 98%
    RX 809055AX is a potent long lasting opioid antagonist with selectivity towards at mu and delta receptors.
    RX809055AX
  • HY-123145
    JNJ-10258859 374927-03-4 98%
    JNJ-10258859 is a potent and selective phosphodiesterase type 5 inhibitor, with a Ki of 0.23 nM. JNJ-10258859 can be used for erectile dysfunction research.
    JNJ-10258859
  • HY-123182
    PD-140548 140677-01-6 98%
    PD-140548 is a selective cholecystokinin (CCKA) receptor antagonist. PD-140548 can be used in schizophrenia research.
    PD-140548
  • HY-123228
    CHF5022 749269-77-0 98%
    CHF5022 is an inhibitor of Aβ42 secretion (IC50=92 μM). CHF5022 retains a modest activity on Aβ40 at non-cytotoxic concentrations (−22.2±4.8% at 100 μM).
    CHF5022
  • HY-123302
    CID1172084 459848-10-3 98%
    CID1172084 (compound 3) is a selective GPR55 agonist (EC50=0.16 μM). CID1172084 is more than 100-fold selective for GPR55 over GPR35, CB1, and CB2. CID1172084 can be used to further explore the biological functions and signaling pathways of the GPR55 receptor.
    CID1172084
  • HY-12332R
    JW 642 (Standard) 1416133-89-5 98%
    JW 642 (Standard) is the analytical standard of JW 642. This product is intended for research and analytical applications.
    JW 642 (Standard)
  • HY-123374
    (Rac)-AMG 628 862269-73-6 98%
    (Rac)-AMG 628 is the racemate of AMG 628, a potent TRPV1 antagonist with an IC50 of 3.7nM. AMG 628 can be used in chronic pain research.
    (Rac)-AMG 628
  • HY-123440
    S3608 57359-17-8 98%
    S3608 is an atypical dopamine agonist. S3608 dose dependently increase locomotor activity (LA) in rats.
    S3608
  • HY-12347R
    Ro 61-8048 (Standard) 199666-03-0 98%
    Ro 61-8048 (Standard) is the analytical standard of Ro 61-8048. This product is intended for research and analytical applications. Ro 61-8048 is an orally active and selective inhibitor of kynurenine 3-hydroxylase, with an IC50 of 37 nM. Ro 61-8048 provokes a significant increase of extracellular kynurenic acid concentrations.
    Ro 61-8048 (Standard)
  • HY-123498
    MCI-225 (dehydratase) 99487-26-0 98%
    MCI-225 dehydratase is an orally active and selective noradrenaline reuptake inhibitor. MCI-225 dehydratase also is a 5-HT3 antagonist and shows antidepressant effects in vivo.
    MCI-225 (dehydratase)
  • HY-123556
    SZV-558 1648929-13-8 98%
    SZV-558 is a potent and selective MAO-B inhibitor with IC50 values of 50 and 60 nM for rats and humans, respectively. SZV-558 can be used in studies of Parkinson's disease (PD) models.
    SZV-558
  • HY-12355R
    Siponimod (Standard) 1230487-00-9 98%
    Siponimod (BAF-312) (Standard) is the analytical standard of Siponimod. This product is intended for research and analytical applications. Siponimod is an orally active, blood-brain barrier penetrant dual agonist of S1P1/S1P5, with EC50 values of 0.39 nM and 0.98 nM, respectively. Siponimod induces S1P1 internalization, activates GIRK channels, inhibits lymphocyte egress, reduces peripheral lymphocyte counts, triggers transient bradycardia, prevents synaptic neurodegeneration, promotes remyelination, alleviates demyelination, and prevents the loss of GABAergic interneurons. Siponimod can be used in research related to multiple sclerosis.
    Siponimod (Standard)
  • HY-123582
    CP-866,087 519052-02-9 98%
    CP-866,087 is a novel, potent and selective μ-opioid receptor antagonist with activity to inhibit opioid effects. CP-866,087 has shown promising preclinical efficacy data in disease models associated with alcohol consumption. CP-866,087 has also been used to study female sexual dysfunction.
    CP-866,087
  • HY-123602
    CGP 55802A 152564-63-1 98%
    CGP 55802A is a novel photoaffinity ligand for in situ labeling of NMDA receptors with high selectivity for the glutamate recognition site.
    CGP 55802A
  • HY-123663
    U-101958 maleate 224170-09-6 98%
    U-101958 (PNU-101958) maleate is a highly selective ligand and antagonist for dopamine D4 receptor, with an IC50 of 2.7 nM. U-101958 maleate behaves as an agonist in HEK-293 cells expressing the human recombinant D4.4 receptor. U-101958 maleate is an antipsychotic.
    U-101958 maleate
Cat. No. Product Name / Synonyms Application Reactivity